10-Q

Quarterly Report

Kiromic Biopharma, Inc.

0001558370-24-007715

← back to feed

Filed

2 years ago May 10, 2024 12:00 AM ET

Period of report

—

On SEC.gov

Filing index ↗

Financials in this filing

Metric	Period	Value
Shares Outstanding	Q1 2024 · May 8, 2024	1.29M sh
Shares Diluted	Q1 2024 · Mar 31, 2024	1.3M sh
Shares Diluted	Q1 2024 · Mar 31, 2023	872.82K sh
Capex	Q1 2024 · Mar 31, 2024	$21K
Operating Cash Flow	Q1 2024 · Mar 31, 2024	−$5.7M
Operating Cash Flow restated	Q1 2024 · Mar 31, 2023	−$4.13M
Short Term Debt	Q1 2024 · Mar 31, 2024	$192K
Cash And Equivalents	Q1 2024 · Mar 31, 2024	$3.68M
Cash And Equivalents	Q1 2024 · Dec 31, 2023	$3.2M
Stockholders Equity	Q1 2024 · Mar 31, 2024	−$7.21M
Stockholders Equity	Q1 2024 · Dec 31, 2023	−$9.12M
Stockholders Equity restated	Q1 2024 · Mar 31, 2023	−$8.14M
Stockholders Equity restated	Q1 2024 · Dec 31, 2022	−$5.78M
Current Liabilities	Q1 2024 · Mar 31, 2024	$19.09M
Current Liabilities	Q1 2024 · Dec 31, 2023	$20.38M
Total Liabilities	Q1 2024 · Mar 31, 2024	$19.84M
Total Liabilities	Q1 2024 · Dec 31, 2023	$21.29M
Current Assets	Q1 2024 · Mar 31, 2024	$5.57M
Current Assets	Q1 2024 · Dec 31, 2023	$4.43M
Total Assets	Q1 2024 · Mar 31, 2024	$12.63M
Total Assets	Q1 2024 · Dec 31, 2023	$12.17M
Eps Diluted	Q1 2024 · Mar 31, 2024	−$1.00
Eps Diluted	Q1 2024 · Mar 31, 2023	−$6.17
Eps Basic	Q1 2024 · Mar 31, 2024	−$1.00
Eps Basic	Q1 2024 · Mar 31, 2023	−$6.17
Sga Expense	Q1 2024 · Mar 31, 2024	$2.09M
Sga Expense restated	Q1 2024 · Mar 31, 2023	$2.7M
Rd Expense	Q1 2024 · Mar 31, 2024	$3.02M
Rd Expense	Q1 2024 · Mar 31, 2023	$2.08M
Net Income	Q1 2024 · Mar 31, 2024	−$6.15M
Net Income restated	Q1 2024 · Mar 31, 2023	−$5.3M
Operating Income	Q1 2024 · Mar 31, 2024	−$5.11M
Operating Income restated	Q1 2024 · Mar 31, 2023	−$4.78M